What Galien does

Galien is a France-based Contract Development and Manufacturing Organization (CDMO) serving international pharmaceutical companies across more than 60 countries. Founded in 1990 and headquartered in Levallois-Perret, the company operates through two wholly-owned French legal entities (GALIEN LPS and GALIEN MACORS) and runs a multi-site industrial network spanning five locations: Levallois-Perret (general management), Nevers (LYOC/LyoDis oral lyophilisates), Auxerre (solid forms, sachets, high potent products), Sens (dry-form packaging) and Monéteau (warehouse). The firm employs approximately 550 people and produces roughly 150 million boxes, 4 billion tablets and capsules, 650+ million sachets and 500 million oral lyophilisates per year, handling 167 active pharmaceutical ingredients and 612 packaged products across 8,600 lots annually.

Galien's core technology is built around specialized pharmaceutical dosage forms. Its proprietary LyoDis (and LYOC) oral lyophilizate platform — produced exclusively at Nevers — generates an instantly dissolving, orodispersible porous matrix that supports up to five years of stability and can confer molecule exclusivity and FDA 505b2 first-to-file positioning to clients. The company also operates a dedicated High Potent Products unit at Auxerre handling OEB1–OEB5 classification for more than 50 molecules, plus comprehensive solid form (tablets, dragees, capsules), sachet, multi-technology packaging (PVC/PVDC/Aclar/Alu-Alu blisters, pill jars, stacked tubes) and serialization capabilities certified under EU Falsified Medicines Directive 2011/62/EU. Site operations are further supported by Industry 4.0 infrastructure including Industrial IoT, connected freezers, semi-robotic warehousing and automated TRS/OEE calculation. Regulatory coverage spans ANSM (French MoH), US FDA, Russian, Turkish, ANVISA (Brazil, in progress), Kuwait, UAE, GCC-DR and Lebanese authorities.

Galien generates revenue as a contract manufacturer, with pricing negotiated project-by-project under multi-year contracts and billed through professional-services arrangements. The go-to-market is direct enterprise field sales: dedicated contact forms for business development and new projects, with no listed channel partners, distributors or public pricing. The company sells primarily to international pharmaceutical companies requiring development, manufacturing and packaging of high-value-added dosage forms (oral lyophilizates, high potent compounds, specialty sachets) that these clients choose to outsource rather than build in-house. Supporting services — pharmaceutical development with pilot/clinical batches, graphic studio, technical and regulatory assistance (CTD format, ICH Q3D), and analytical/stability services — extend the offering across the molecule lifecycle from pre-formulation through commercial supply.

Name

Galien

Legal name

GALIEN LPS

Website

https://galien.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

101–250 employees

Short description

Galien is a French CDMO founded in 1990 that develops and manufactures high-value pharmaceutical dosage forms — including proprietary LyoDis oral lyophilizates, high potent products (OEB1–OEB5), solid forms, sachets and serialized packaging — for international pharmaceutical companies across more than 60 countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Lyophilization (Freeze-Drying) CDMO (HLAGABAI), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Pharmaceutical contract manufacturing
• Oral lyophilizate technology
• High potent drug manufacturing
• Pharmaceutical packaging services
• Solid dosage form production

Headquarters

HQ city

Nevers

HQ country

France

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: CDMO services providing development and manufacturing of pharmaceutical products including oral lyophilizates, high potent products, solid forms, sachets, and packaging. Revenue generated through long-term partnerships with international pharmaceutical companies requiring specialized manufacturing capabilities.
2. Pharmaceutical Packaging Services: Conditioning and packaging services for tablets, capsules, soft capsules in various formats including blisters, pill jars, and tubes. Includes serialization services.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Galien is a French Contract Development and Manufacturing Organization (CDMO) that develops, manufactures, and packages high-tech pharmaceutical drug products for international pharmaceutical companies. Core offerings include proprietary LyoDis® oral lyophilizate technology, solid forms (tablets, dragees, capsules), high potent products (OEB1-OEB5), sachet forms, and serialization-enabled packaging services, with supporting development, regulatory, and analytical services.

Product overview

Galien is a Contract Development and Manufacturing Organization (CDMO) offering a unified portfolio of pharmaceutical manufacturing and packaging services. The core offerings include proprietary LyoDis® oral lyophilizate technology (produced exclusively at the Nevers site), solid forms (tablets, dragees, capsules), high potent products (OEB1-OEB5), sachet forms, and packaging services with serialization capabilities. Supporting services include pharmaceutical development with pilot/clinical batch capabilities, graphic studio, technical/regulatory assistance, and analytical services. The company operates multiple specialized sites including Auxerre (solid forms, sachets, high potent), Nevers (oral lyophilizates), Sens (packaging), and Monéteau (warehouse), unified under a common quality system.

Differentiator

Problem solved

Functional benefit

Products and services

• LyoDis® Oral Lyophilizate Proprietary orodispersible lyophilizate technology producing a porous, instantly dissolving tablet that disperses in the mouth without water. Manufactured at the Nevers site with capacity of 50 million blisters (500 million oral lyophilisates) and offers molecule exclusivity to clients.
• Pharmaceutical Development Services New product development services for dry forms, high potent products, and oral lyophilizates. Includes pilot and clinical batch manufacturing, pre-formulation studies, and regulatory support for FDA 505b2 submissions.
• Sachet Forms Contract sachet production with over 30 years of experience and one of the largest capacities in Europe (650+ million sachets annually). Handles filling masses from milligrams to hundreds of grams with environmental control capabilities.
• Solid Forms (Tablets, Dragees, Capsules) Production of compressed tablets (naked and film-coated), sugar-coated dragees with over 20 years of experience, and capsules in sizes 00, 0, 1, 2, 3 and 4. Annual capacity of 4 billion tablets and capsules at the Auxerre site.
• High Potent Products (OEB1-OEB5) Dedicated manufacturing and packaging unit for highly active pharmaceutical ingredients at the Auxerre site. Handles over 50 different molecules including tablets, dragees, capsules, and sachets, with annual capacity of 40 million blisters.
• Packaging Services Multi-technology packaging for tablets, capsules, and soft capsules including PVC/PVDC/Aclar/Alu-Alu blisters, pill jars (20-100ml), and stacked tubes for effervescent tablets. Includes serialization capabilities compliant with European directive 2011/62/EU.
• Graphic Studio Services Design services including infographics, packaging artwork creation, 3D pack visuals, pressbook management, pictogram creation, and mock-ups for readability testing.
• Technical and Regulatory Assistance Regulatory services including industrial expertise for post-AMM issues, CTD format registration updates, pharmaceutical variations, change control projects, and ICH Q3D elemental impurities compliance support.
• Analytical Services ICH and ongoing stability studies with 24/7 temperature and humidity monitoring, raw material and finished product testing, HPLC to UPLC method optimization, and trend analysis reporting.

Quantifiable outcome

• Up to 5 years stability for LyoDis products
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Recipharm: European CDMO offering solid dose, semi-solids, sterile, and packaging services across numerous sites. Comparable as a European-headquartered contract manufacturer serving international pharma clients with broad solid oral form capabilities.
• Delpharm: French CDMO specializing in solid oral dosage forms, sterile injectables, and packaging with multiple French and European sites. Closely comparable to Galien in scale, French footprint, and solid oral dose CDMO positioning.
• Fareva: French-headquartered CDMO with multiple manufacturing sites across Europe offering solid oral forms, sterile fill-finish, and packaging services. Most directly comparable to Galien by geography, customer type (international pharma), and mix of solid-dose and packaging services.
• Aenova: European CDMO with strong capabilities in solid oral forms, softgel, and packaging. Comparable to Galien in solid dose manufacturing focus, multi-site European footprint, and contract service model.
• Cenexi: French CDMO focused on sterile and solid dose forms with sites in France. Comparable to Galien as a French-based mid-size contract manufacturer serving international pharma clients.
• NextPharma: European CDMO offering solid, semi-solid, and sterile dosage forms plus packaging services. Comparable to Galien in multi-site European footprint, broad CDMO service mix, and international pharma client base.
• Unither Pharmaceuticals: French CDMO specializing in sterile unit-dose forms including lyophilized orodispersible tablets and blow-fill-seal liquids. Most direct comparable to Galien's LyoDis oral lyophilizate business and CDMO model serving pharma clients globally.
• Hovione: Specialty CDMO with strong capabilities in spray drying, particle engineering, and lyophilization. Comparable to Galien in offering differentiated, science-driven dosage form technology and serving international pharma clients with high-value CDMO services.

Broad incumbents

• Catalent: Large global CDMO with extensive oral solid, sterile, biologic, and softgel capabilities. Comparable as a broad incumbent competing for the same pharma outsourcing spend though at materially greater scale and geographic breadth than Galien.
• Siegfried: Swiss-listed CDMO with global manufacturing footprint covering APIs, solid oral forms, and sterile manufacturing. Comparable as a broader incumbent in the European CDMO space competing for similar pharma outsourcing contracts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/GalienCom

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galien